Navigation Links
Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
Date:12/13/2010

ietary PIM Conjugate Technology is being employed to improve the absorption and distribution profile of tenofovir, with the goal of increasing antiviral efficacy while decreasing potential toxicity. Chimerix is developing CMX157 for the treatment of patients who are refractory to or not sufficiently treated by existing HIV therapies.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus.  Over 325 people have received CMX001 to date.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  In Chimerix's ongoing placebo-controlled studies, CMX001 has been administered to more than 200 patients and healthy volunteers.  In addition, at the request of leading physicians at over 45 medical centers throughout the United States, Canada, Europe and Israel, CMX001 has been administered to more than 125 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which there are either no approved treatments or where patients have failed the available treatment.  To date, CMX001 has been used to treat patients with 12 different dsDNA viral infections across all five families of dsDNA viruses that affect humans. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant funding from the National Institutes of Allergy and Infectious Disease to develop CMX001 for smallpox.

Chimerix's second clinical-stage antiviral compound, C
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Custom Spine, a company dedicated to offering advanced spinal ... North American Spine Society,s (NASS) annual meeting being held ... a unique articulating vertebral interbody device, which consists of ... the disc space. The interbody is inserted in ...
... CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer ... the IVD testing market, was featured in Medical ... article by Amanda Petersen, titled "CardioGenics aims to offer ... Yahia Gawad, MD regarding the company,s point-of-care (POC) cardiac ...
Cached Medicine Technology:Custom Spine Launches Pathway AVID and Regent ACP at NASS 2CardioGenics Holdings Inc. Featured in Medical Device Daily 2CardioGenics Holdings Inc. Featured in Medical Device Daily 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Molecules from cone snail venom and African plants are being ... oral drug to treat chronic pain. , Professor David ... Bioscience have received $218,275 from the National Health and Medical ... a product available for Australians to use. , Studies ...
... severe symptom reported by middle-aged women when their periods change ... study in the April issue of the UK-based Journal of ... of Nursing, USA, spoke to 110 women entering the menopause ... at longer or shorter intervals. Their average age was 49 ...
... RuiTai International Holdings Co., Ltd. (OTC Bulletin Board: ... and distributor,of cellulose ether products in the People,s ... for the fiscal year ended December,31, 2007., ... increased 36.7% to $38.4 million -- Gross ...
... Executive brings extensive experience in both healthcare and human ... ... 16 Precyse Solutions, the leader in,driving peak performance within Health ... Corporate,Vice President of Human Resources. She joins Precyse from Pegasus,Communications where ...
... next President to focus more on improving their,standard ... of jobs overseas than making it easier for ... to the latest "America At Work" national,opinion survey ... The workplace-issues poll, based on a sampling of ...
... It may produce chemicals that protect the brain, ... -- Regular physical exercise may help protect against ... study. , People with mild cognitive impairment can ... details of conversations, events and upcoming appointments. Most, ...
Cached Medicine News:Health News:Cone snails and plants used to develop oral drug for pain 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 2Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 3Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 4Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 5Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 6Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 7Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 8Health News:China RuiTai Reports Fiscal Year 2007 Financial Results 9Health News:Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 2Health News:Americans Want Next President to Focus More on Saving U.S. Jobs and Healthcare; Less on Immigration Reform 3Health News:Exercise Could Cut Risk of Mild Cognitive Impairment 2
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
The family of Passive Plus DX passive-fixation leads features a 5 mm tip, designed to increase current density and pacing impedance, and a tine fixation, offering versatility and security in lead pla...
... The IsoFlex S lead's small ... ease implantation and lower the ... smaller, more tortuous vessels. Atrial ... and fixation options combine to ...
Unipolar Atrial "J" Lead...
Medicine Products: